Ryuta Asada, PhD

Gifu University Hospital
Innovative and Clinical Research Promotion Center
Gifu Japan Papers:
2924 Phase II Trial of CH5424802 (alectinib hydrochloride) for Recurrent or Refractory ALK-Positive Anaplastic Large Cell Lymphoma